Reversible Inhibitors of Monoamine Oxidase

Known as: Reversible Inhibitor of Monoamine Oxidase 
RIMA shows preference for the A isoenzyme
National Institutes of Health

Topic mentions per year

Topic mentions per year

1977-2017
0246819772017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Recent reports document that α-tetralone (3,4-dihydro-2H-naphthalen-1-one) is an appropriate scaffold for the design of high… (More)
Is this relevant?
2012
2012
Methylene blue (MB) has been shown to act at multiple cellular and molecular targets and as a result possesses diverse medical… (More)
Is this relevant?
1999
1999
The reversible inhibitors of monoamine oxidase type A (RIMAs) are a newer group of antidepressants that have had much less impact… (More)
  • table 1
  • table 3
  • table 4
  • table 4
  • figure 1
Is this relevant?
1995
1995
The clinically tested reversible inhibitors of monoamine oxidase A (RIMAs) include brofaromine, moclobemide and toloxatone… (More)
Is this relevant?
1993
1993
The effects of reversible inhibitors of monoamine oxidase-A (moclobemide, Ro 41-1049, both 20 mg/kg, i.p., and brofaromine, 10 mg… (More)
Is this relevant?
1990
1990
The design and the main therapeutic results of 3 controlled double-blind studies comparing moclobemide with tricyclics and/or… (More)
Is this relevant?
1990
1990
Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic… (More)
Is this relevant?
1989
1989
Moclobemide belongs to a new generation of short-acting, reversible, monoamine oxidase (MAO) inhibitors. In vitro (rat brain… (More)
Is this relevant?
1988
1988
Intraperitoneal injection of cimoxatone, moclobemide, amiflamine CGP 11305 A (all 5 mg/kg) increased pressor responses to… (More)
Is this relevant?
1981
1981
1 A number of aromatic-N-propargyl (acetylenic) compounds and indoleamines were tested for their inhibitory action on monoamine… (More)
Is this relevant?